Sugi Predict

Sugi Predict / Compounds / SCHEMBL282212

SCHEMBL282212

SCHEMBL282212

COc1cc2c(Cl)ccnc2cc1F

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 2/20 0.48
▸ CGAS Q8N884 1/20 0.46
▸ KDR P35968 3/20 0.45
▸ EGFR P00533 4/20 0.44
▸ PDGFRB P09619 2/20 0.44
▸ AURKA O14965 1/20 0.44
▸ ERBB2 P04626 1/20 0.44
▸ INSR P06213 1/20 0.44
▸ FBP1 P09467 1/20 0.44
▸ FLT4 P35916 1/20 0.44
▸ CLK1 P49759 1/20 0.44
▸ EPHB4 P54760 1/20 0.44
▸ TEK Q02763 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ FGFR1 P11362 2/20 0.44
▸ FLT1 P17948 2/20 0.44
▸ PDGFRA P16234 1/20 0.43
▸ TRPA1 O75762 2/20 0.43
▸ FGFR2 P21802 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6004195 0.94 SRC (0.48) SRCCGASKDREGFRPDGFRB
SCHEMBL29576504 0.86 SRC (0.60) SRCCGASEGFRPDGFRBPDGFRA
SCHEMBL359988 0.86 SRC (0.60) SRCCGASEGFRPDGFRBPDGFRA
SCHEMBL29387468 0.86 SRC (0.60) SRCCGASEGFRPDGFRBPDGFRA
SCHEMBL6004164 0.85 CGAS (0.59) SRCCGASEGFRPDGFRBPDGFRA
Hydrochloric Acid SCHEMBL6432173 0.85 SRC (0.58) SRCCGASEGFRPDGFRBPDGFRA
SCHEMBL3905974 0.82 SRC (0.49) SRCCGASEGFRPDGFRBPDGFRA
SCHEMBL25606792 0.82 PDPK1 (0.47) SRCEGFRPDGFRBPDGFRATRPA1
SCHEMBL24008989 0.81 SRC (0.58) SRCCGASEGFRPDGFRBPDGFRA
SCHEMBL22441533 0.81 SRC (0.52) SRCKDREGFRPDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 — — US disclosed
EP-4374928-A2 NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING The Brigham And Women's Hospital Inc. (US) 2024-05-29 — — EP disclosed
EP-3615538-B1 NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING BRIGHAM & WOMENS HOSPITAL INC (US) 2024-02-07 — — EP disclosed
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 — — US disclosed
EP-4214199-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 — — EP disclosed
CN-116490503-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-07-25 — — CN disclosed
US-11654147-B2 ALK2 inhibitors and methods for inhibiting BMP signaling THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2023-05-23 — — US disclosed
US-11654147-B2 ALK2 inhibitors and methods for inhibiting BMP signaling THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2023-05-23 — — US disclosed
US-11654147-B2 ALK2 inhibitors and methods for inhibiting BMP signaling THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2023-05-23 — — US disclosed
CN-111164083-B Novel ALK2 inhibitors and methods for inhibiting BMP signaling 布里格姆妇女医院股份有限公司 2023-01-10 — — CN disclosed
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 — — US disclosed
EP-2428506-B1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) 2014-03-05 — — EP disclosed
EP-2428506-A1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF Jiangsu Provincial Institute Of Materia Medica Co. (CN) 2012-03-14 — — EP disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 — — US disclosed
US-7973164-B2 Quinoline derivatives ASTRAZENECA AB (SE) 2011-07-05 — — US disclosed
CN-101437811-A Quinoline derivatives ASTRAZENECA AB (SE) 2009-05-20 — — CN disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 — — US disclosed
EP-1994025-A1 QUINOLINE DERIVATIVES AstraZeneca AB (SE) 2008-11-26 — — EP disclosed
WO-2007099326-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 — — WO disclosed
EP-1724268-A1 COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS CSNK1D, CSNK1A1, CSNK2A1 SRC 392/4885CGAS 2834/4885KDR 3943/4885
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 SRC 842/4885CGAS 2528/4885KDR 3633/4885
US-11654147-B2 ALK2 inhibitors and methods for inhibiting BMP signaling BMPR2, BMP1, BMP2K SRC 3220/4885CGAS 696/4885KDR 36/4885
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 SRC 1835/4885CGAS 664/4885KDR 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.